NYKD Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nykode Therapeutics AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.75 |
| 52 Week High | NOK 21.40 |
| 52 Week Low | NOK 1.55 |
| Beta | 1.31 |
| 11 Month Change | -46.45% |
| 3 Month Change | -52.38% |
| 1 Year Change | -86.51% |
| 33 Year Change | -96.39% |
| 5 Year Change | n/a |
| Change since IPO | -86.11% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Nykode Therapeutics' (OB:NYKD) Cash Burn Rate
Aug 05
Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 02Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)
Jan 22We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth
Aug 20Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business
Apr 06Could The Vaccibody AS (OB:VACC) Ownership Structure Tell Us Something Useful?
Jan 25
Shareholder Returns
| NYKD | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | 26.8% | 8.9% | 3.1% |
| 1Y | -86.5% | -69.4% | 3.9% |
Return vs Industry: NYKD underperformed the Norwegian Biotechs industry which returned -70.5% over the past year.
Return vs Market: NYKD underperformed the Norwegian Market which returned 2.5% over the past year.
Price Volatility
| NYKD volatility | |
|---|---|
| NYKD Average Weekly Movement | 20.2% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: NYKD's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: NYKD's weekly volatility has increased from 12% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 179 | Michael Engsig | nykode.com |
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10
Nykode Therapeutics AS Fundamentals Summary
| NYKD fundamental statistics | |
|---|---|
| Market cap | NOK 898.00m |
| Earnings (TTM) | -NOK 419.45m |
| Revenue (TTM) | NOK 72.09m |
12.5x
P/S Ratio-2.1x
P/E RatioIs NYKD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NYKD income statement (TTM) | |
|---|---|
| Revenue | US$6.52m |
| Cost of Revenue | US$0 |
| Gross Profit | US$6.52m |
| Other Expenses | US$44.43m |
| Earnings | -US$37.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 27, 2024
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 100.00% |
| Net Profit Margin | -581.88% |
| Debt/Equity Ratio | 0% |
How did NYKD perform over the long term?
See historical performance and comparison